Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- antígeno prostático específico (PSA) elevado
Outros fatores diagnósticos
- exame de toque retal (ETR) anormal
- noctúria
- polaciúria
- hesitação urinária
- disúria
- hematúria
- perda de peso/anorexia
- letargia
- dor óssea
- linfonodos palpáveis
Fatores de risco
- idade >50 anos
- etnia negra
- Populações do norte da Europa, Caribe, Austrália, Nova Zelândia, América do Norte e sul da África
- história familiar positiva/fatores genéticos
- alimentação com alto teor de gordura
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- antígeno prostático específico (PSA) sérico
- RNM multiparamétrica pré-biópsia
- biópsia de próstata
Investigações a serem consideradas
- testes de biomarcadores pré-biópsia e calculadoras de risco
- testosterona
- TFHs
- Hemograma completo
- função renal
- cintilografia óssea (tecnécio-99)
- Tomografia computadorizada (TC)
- RNM
- antígeno de membrana específico da próstata (PSMA)-PET/CT
- PSMA-PET/MRI
- testes moleculares e genéticos de tumores
- avaliação genética e testes de linha germinativa
Algoritmo de tratamento
doença de muito baixo risco
doença de baixo risco
doença de risco intermediário favorável
doença de risco intermediário desfavorável
doença de alto risco ou risco muito alto
doença não metastática: pós-prostatectomia radical
doença não metastática: pós-radioterapia
doença não metastática: resistente à castração
doença metastática: sensível à castração
doença metastática: resistente à castração
Colaboradores
Autores
Timothy J. Wallace, MD, PhD
Radiation Oncologist
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
Declarações
TJW declares that he has no competing interests.
Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Professor Emeritus
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
利益声明
MSA declares that he has no competing interests.
同行评议者
Emma Alexander, MBBS
Clinical Oncology Registrar
St Luke's Cancer Centre
Royal Surrey Hospital
Guildford
Surrey
UK
利益声明
EA has received consultation fees from the following organisations: Blue Cross/Blue Shield Association, Sanofi-Aventis, Ferring Pharmaceuticals, Pfizer Corporation, American Urological Association, National Institutes of Health, Accreditation Council for Graduate Medical Education, Royal Hallamshire Hospital, Hartford County Medical Association. EA owns shares in Pfizer Pharmaceuticals, Johnson and Johnson, and General Electric Corporation.
Peter Albertsen, MD
Medical Director
UConn Medical Group
University of Connecticut Health Center
Farmington
CT
利益声明
PA declares that he has no competing interests.
Patrick C. Walsh, MD
University Distinguished Service Professor of Urology
Professor Emeritus of Urology
Brady Urological Institute
Johns Hopkins University
Baltimore
MD
利益声明
PCW declares that he has no competing interests.
James Kearns, MD
Assistant Professor of Urology
NorthShore University HealthSystem
Chicago
IL
利益声明
JK declares that he has no competing interests. JK is an author of an article cited in the topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer [internet publication].全文
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection [internet publication].全文
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-34.全文 摘要
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018 Oct 11;36(34):JCO1801097.全文 摘要
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024 Apr;211(4):509-17.全文 摘要
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024 Apr;211(4):518-25.全文 摘要
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024 Apr;211(4):526-32.全文 摘要
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
鉴别诊断
- Hiperplasia prostática benigna
- Prostatite crônica
更多 鉴别诊断指南
- NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment breast, ovarian, pancreatic, and prostate
- NCCN clinical practice guidelines in oncology: prostate cancer early detection
更多 指南患者教育信息
Câncer de próstata
Câncer de próstata: perguntas a fazer ao seu médico
更多 患者教育信息医学计算器
Escore de sintomas prostáticos
更多 医学计算器Videos
Cateterismo uretral masculino - Vídeo de demonstração
更多 操作视频
登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容
内容使用需遵循免责声明